More about

Sglt2 Inhibitor

News
December 13, 2023
1 min read
Save

Top in endocrinology: PFAS linked to thyroid cancer; non-insulin agents in type 1 diabetes

Top in endocrinology: PFAS linked to thyroid cancer; non-insulin agents in type 1 diabetes

Adults who were exposed to higher levels of endocrine-disrupting chemicals were more likely to be diagnosed with thyroid cancer, according to a study published in eBioMedicine.

News
December 07, 2023
4 min read
Save

What to know about using non-insulin agents in type 1 diabetes

What to know about using non-insulin agents in type 1 diabetes

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, about nuances of using SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes, and a therapy for delaying type 1 diabetes onset.

News
November 15, 2023
2 min read
Save

SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus

SGLT2 inhibitors have ‘potential role’ in reducing cardiac, renal risks in lupus

SAN DIEGO — Patients with lupus who received sodium-glucose cotransporter-2 inhibitors demonstrated reduced risks for major adverse cardiovascular events and kidney disease, a speaker said at ACR Convergence 2023.

News
November 12, 2023
3 min read
Save

Women at significant risk for urinary, genital infections while using SGLT2i

Women at significant risk for urinary, genital infections while using SGLT2i

SAN DIEGO — Women with autoimmune and rheumatic conditions are at a significant risk for adverse events during treatment with sodium glucose cotransporter 2 inhibitors, according to data presented at ACR Convergence 2023.

News
September 28, 2023
3 min read
Save

For older adults with diabetes, CV risk lower with SGLT2 or GLP-1 vs. DPP-IV therapy

For older adults with diabetes, CV risk lower with SGLT2 or GLP-1 vs. DPP-IV therapy

Older adults with type 2 diabetes are less likely to have a cardiovascular event if they are initially prescribed an SGLT2 inhibitor or GLP-1 receptor agonist instead of a DPP-IV inhibitor, according to findings published in Diabetes Care.

News
September 06, 2023
2 min read
Save

Top in cardiology: 5 risk factors cause most CVD; SGLT2 inhibitors ineffective in COVID-19

Top in cardiology: 5 risk factors cause most CVD; SGLT2 inhibitors ineffective in COVID-19

A study conducted by the Global Cardiovascular Risk Consortium found that five modifiable risk factors accounted for more than half of cases of cardiovascular disease in men and women and 20% of deaths in both sexes.

News
August 17, 2023
4 min read
Save

SGLT2 inhibitors preferred for adults with type 2 diabetes and heart failure

SGLT2 inhibitors preferred for adults with type 2 diabetes and heart failure

HOUSTON — SGLT2 inhibitors should be the first choice of therapy for adults with type 2 diabetes and heart failure, according to two speakers at the Association of Diabetes Care and Education Specialists annual meeting.

News
August 14, 2023
7 min watch
Save

VIDEO: Medication advancements impacted by diabetes technology innovations

VIDEO: Medication advancements impacted by diabetes technology innovations

Healio spoke with David Klonoff, MD, about the latest innovations in diabetes medications.

News
July 27, 2023
2 min read
Save

SGLT2 inhibitors may reduce recurrent gout flares in patients with type 2 diabetes

SGLT2 inhibitors may reduce recurrent gout flares in patients with type 2 diabetes

SGLT2 inhibitors were associated with a reduction in recurrent flares and gout-related ED visits among patients with type 2 diabetes and gout, according to research published in Annals of Internal Medicine.

News
June 06, 2023
3 min read
Save

SGLT2 inhibitors may reduce cancer risks among adults with diabetes

SGLT2 inhibitors may reduce cancer risks among adults with diabetes

Adults with diabetes who use SGLT2 inhibitors have lower risks for developing most types of cancer compared with nonusers, though the risk for pancreatic cancer is higher among SGLT2 users, according to data from researchers in Taiwan.

View more